Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival

Surgical Oncology

Volumn 21, Issue 4, 2012, Pages 309-315

  Gruenberger, T ^a   Arnold, D ^b   Rubbia Brandt, L ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bevacizumab; Colorectal cancer; Hepatic resection; Liver metastases; Pathologic response; Survival

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; HUMAN; LIVER METASTASIS; LIVER RESECTION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84867881665     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2012.07.003     Document Type: Review

References (42)

1. H.L. Kindler, and K.L. Shulman Metastatic colorectal cancer Curr Treat Options Oncol 2 6 2001 459 471
2. L. Weiss, E. Grundmann, J. Torhorst, F. Hartveit, I. Moberg, and M. Eder Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies J Pathol 150 3 1986 195 203
3. S. Kopetz, G.J. Chang, M.J. Overman, C. Eng, D.J. Sargent, and D.W. Larson Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 22 2009 3677 3683
4. A. Okines, O.D. Puerto, D. Cunningham, I. Chau, E. Van Cutsem, and L. Saltz Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial Br J Cancer 101 7 2009 1033 1038
5. B. Nordlinger, E. van Cutsem, T. Gruenberger, B. Glimelius, G. Poston, and P. Rougier Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Ann Oncol 20 6 2009 985 992
6. B. Nordlinger, H. Sorbye, B. Glimelius, G.J. Poston, P.M. Schlag, and P. Rougier Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 9617 2008 1007 1016
7. G. Folprecht, T. Gruenberger, W.O. Bechstein, H.R. Raab, F. Lordick, and J.T. Hartmann Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11 1 2010 38 47
8. R. Wong, C. Saffery, Y. Barbachano, I. Chau, J. Valle, and T. Hickish BOXER: a multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection Eur J Cancer Suppl 7 2 2009 344 345
9. S. Zakaria, J.H. Donohue, F.G. Que, M.B. Farnell, C.D. Schleck, and D.M. Ilstrup Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 246 2 2007 183 191
10. G. Folprecht, T. Gruenberger, W. Bechstein, F. Lordick, H. Lang, and J. Weitz Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study J Clin Oncol 30 Suppl. 4 2012 Abstract 540
11. B. Nordlinger, M. Guiguet, J.C. Vaillant, P. Balladur, K. Boudjema, and P. Bachellier Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients Cancer 77 7 1996 1254 1262
12. M.C. de Jong, C. Pulitano, D. Ribero, J. Strub, G. Mentha, and R.D. Schulick Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients Ann Surg 250 3 2009 440 448
13. K.R. Stephenson, S.M. Steinberg, K.S. Hughes, J.T. Vetto, P.H. Sugarbaker, and A.E. Chang Perioperative blood transfusions are associated with reduced time to recurrence and decreased survival after resection of colorectal liver metastases Ann Surg 208 6 1998 679 687
14. R.N. Younes, A. Rogatko, and M.F. Brennan The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases Ann Surg 214 2 1991 107 113
15. Y. Fong, J. Fortner, R.L. Sun, M.F. Brennan, and L.H. Blumgart Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann Surg 230 3 1999 309 318 Discussion 318-21
16. J. Dômont, T.M. Pawlik, V. Boige, M. Rose, J.C. Weber, and P.M. Hoff Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis J Clin Oncol 23 13 2005 3086 3093
17. H.Z. Malik, Z.Z. Hamady, R. Adair, R. Finch, A. Al-Mukhtar, and G.J. Toogood Prognostic influence of multiple hepatic metastases from colorectal cancer Eur J Surg Oncol 33 4 2007 468 473
18. M. Rees, P.P. Tekkis, F.K. Welsh, T. O'Rourke, and T.G. John Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients Ann Surg 247 1 2008 125 135
19. H.M. Kuerer, L.A. Newman, T.L. Smith, F.C. Ames, K.K. Hunt, and K. Dhingra Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 2 1999 460 469
20. A. Mandard, F. Dalibard, J. Mandard, J. Marnay, M. Henry-Amar, and J.F. Petiot Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations Cancer 73 11 1994 2680 2686
21. S.G. Swisher, W. Hofstetter, T.T. Wu, A.M. Correa, J.A. Ajani, and R.R. Komaki Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT) Ann Surg 241 5 2005 810 817
22. J.A. Ajani, P.F. Mansfield, N. Janjan, J. Morris, P.W. Pisters, and P.M. Lynch Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma J Clin Oncol 22 14 2004 2774 2780
23. H. Bouzourene, F.T. Bosman, W. Seelentag, M. Matter, and P. Coucke Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy Cancer 94 4 2002 1121 1130
24. C. Rödel, P. Martus, T. Papadoupolos, L. Füzesi, M. Klimpfinger, and R. Fietkau Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer J Clin Oncol 23 34 2005 8688 8696
25. J. Suárez, R. Vera, E. Balén, M. Gómez, F. Arias, and J.M. Lera Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer Colorectal Dis 10 6 2008 563 568
26. M. Maas, P.J. Nelemans, V. Valentini, P. Das, C. Rödel, and L.J. Kuo Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Lancet Oncol 11 9 2010 835 844
27. H.T. Eich, A. Stepien, C. Zimmermann, M. Hellmich, R. Metzger, and A. Hölscher Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer: prognostic significance of tumor regression Strahlenther Onkol 187 4 2011 225 230
28. Y.S. Chun, H.S. Cooper, S.J. Cohen, A. Konski, B. Burtness, and C.S. Denlinger Significance of pathologic response to preoperative therapy in pancreatic cancer Ann Surg Oncol 18 13 2011 3601 3607
29. L.B. Saltz, S. Clarke, E. Diaz-Rubio, W. Scheithauer, A. Figer, and R. Wong Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 12 2008 2013 2019
30. Y.S. Chun, J.-N. Vauthey, P. Boonsirikamchai, D.M. Maru, S. Kopetz, and M. Palavecino Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases JAMA 302 21 2009 2338 2344
31. L. Rubbia-Brandt, E. Giostra, C. Brezault, A.D. Roth, A. Andres, and V. Audard Importance of histological tumour response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery Ann Oncol 18 2 2007 299 304
32. D.G. Blazer III, Y. Kishi, D.M. Maru, S. Kopetz, Y.S. Chun, and M.J. Overman Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases J Clin Oncol 26 33 2008 5344 5351
33. R. Adam, D.A. Wicherts, R.J. de Haas, T. Aloia, F. Lévi, and B. Paule Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 26 10 2008 1635 1641
34. D.M. Maru, S. Kopetz, P. Boonsirikamchai, A. Agarwal, Y.S. Chun, and H. Wang Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases Am J Surg Pathol 34 9 2010 1287 1294
35. Y. Kishi, D. Zorzi, C.M. Contreras, D.M. Maru, S. Kopetz, and D. Ribero Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases Ann Surg Oncol 17 11 2010 2870 2876
36. D. Ribero, H. Wang, M. Donadon, D. Zorzi, M.B. Thomas, and C. Eng Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110 12 2007 2761 2767
37. M. Klinger, D. Tamandl, S. Eipeldauer, S. Hacker, B. Herberger, and K. Kaczirek Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX Ann Surg Oncol 17 8 2010 2059 2065
38. L. Rubbia-Brandt, V. Audard, P. Sartoretti, A.D. Roth, C. Brezault, and M. Le Charpentier Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann Oncol 15 3 2004 460 466
39. H. Nakano, E. Oussoultzoglou, E. Rosso, S. Casnedi, M.P. Chenard-Neu, and P. Dufour Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy Ann Surg 247 1 2008 118 124
40. L. Rubbia-Brandt, G.Y. Lauwers, H. Wang, P.E. Majno, K. Tanabe, and A.X. Zhu Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis Histopathology 56 4 2010 430 439
41. D. Tamandl, M. Klinger, S. Eipeldauer, B. Herberger, K. Kaczirek, and B. Gruenberger Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy Ann Surg Oncol 18 2 2011 421 430
42. H.D. Bear, G. Tang, P. Rastogi, C.E. Geyer Jr., A. Robidoux, and J.N. Atkins Bevacizumab added to neoadjuvant chemotherapy for breast cancer N Engl J Med 366 4 2012 310 320